Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Adm… (NCT07688980) | Clinical Trial Compass
Not Yet RecruitingPhase 1
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
92 participantsStarted 2026-10-30
Plain-language summary
The purpose of this study is to assess the PK, PD, and safety of anifrolumab as SC administration or IV infusion in adult participants with systemic lupus erythematosus (SLE).
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Squamous or basal cell carcinoma of the skin treated with documented curative success ≥ 3 months prior to Day 1.
. Cervical cancer in situ treated with apparent curative success ≥ 1 year prior to Day 1.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Anifrolumab is already approved for lupus — so what would be the benefit of joining this early Phase 1 study focused on how the drug moves through the body, rather than starting on an already-approved treatment right now?
2This trial is comparing giving anifrolumab as a subcutaneous injection versus an intravenous infusion — does the route of administration matter for my particular situation, and is one of those options already available to me outside of a trial?
3Since this is a Phase 1 study primarily measuring drug levels in the blood over just the first four weeks, does that mean we would know less about longer-term safety and effectiveness compared to the data behind currently approved lupus therapies?
4The trial is listed as not yet recruiting — do you know when it's expected to open, and would waiting to see if I qualify delay starting a treatment that might help me sooner?
5Because this study is focused on pharmacokinetics and pharmacodynamics rather than treating my symptoms directly, what would my care look like during the trial if my lupus flared or got worse while participating?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.